https://www.aigom.it/wp-content/uploads/2024/07/loc.acro_.png689700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-31 08:27:382024-07-31 08:28:29AICRO E SIT-WORKSHOP “STUDI CLINICI DECENTRALIZZATI-ESPERIENZE ATTUALI E PROSPETTIVE FUTURE” 16 SETTEMBRE 2024
https://www.aigom.it/wp-content/uploads/2024/07/LOC.ART_.30.7.png1195960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-29 08:44:292024-07-29 08:44:29VULVAR CARCINOMA: STANDARD OF CARE AND PERSPECTIVES.
https://www.aigom.it/wp-content/uploads/2024/07/loc.28.png963700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-22 09:17:592024-11-09 09:05:32AIGOM CONGRESSO NAZIONALE-CARCINOMA DEL POLMONE: QUALI NOVITA’ NEL 2024? V EDIZIONE 28 OTTOBRE 2024-VERONA
https://www.aigom.it/wp-content/uploads/2024/07/ART23.7.png1256960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-22 08:42:442024-07-22 08:54:30ADJUVANT TRASTUZUMAB EMTANSINE VERSUS PACLITAXEL PLUS TRASTUZUMAB FOR STAGE I HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER: 5-YEAR RESULTS AND CORRELATIVE ANALYSES FROM ATEMPT
https://www.aigom.it/wp-content/uploads/2024/07/ART16.7.LOC_.png1272960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-15 07:09:222024-07-15 07:09:22CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2024/07/AIG.LOC_.png403700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-09 10:04:092024-07-10 07:55:36LINEE DI INDIRIZZO SULL’INTEGRAZIONE OSPEDALE-TERRITORIO IN ONCOLOGIA DI AGENAS-MINISTRO DELLA SALUTE 1 LUGLIO 2024
https://www.aigom.it/wp-content/uploads/2024/07/loc.11.10.png795582Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-09 08:15:212024-10-29 10:03:26CARCINOMA METASTATICO:QUALI NOVITA’? 11 OTTOBRE 2024 ROMA
https://www.aigom.it/wp-content/uploads/2024/07/ART09.07.png1172960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-09 07:46:032024-07-09 07:55:25OVERALL SURVIVAL IN PATIENTS WITH ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE RANDOMIZED ENGOT-EN6/GOG-3031/RUBY TRIAL.
https://www.aigom.it/wp-content/uploads/2024/07/ART.02.07.png1211960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-07-01 07:11:442024-07-01 07:35:08LORLATINIB VERSUS CRIZOTINIB IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: 5-YEAR OUTCOMES FROM THE PHASE III CROWN STUDY
